Pharmacies remain an untapped frontier for pharma companies as they evolve into one-stop patient shops for health and wellness needs, according to a new white paper from McCann Health. And pharma should take note.
The research looks at the future of pharmacies, outlining the opportunity and necessity for pharma to work more with them. As pharmacies become the frontline for many patients’ healthcare, building stronger and more engaged relationships with them is key for drugmakers.
“There is danger in generalizing (the pharma and pharmacy relationship), but with that caveat, traditionally, pharma companies have developed strong trade-focused, transactional relationships with pharmacy, presenting them with products and deals as distribution intermediaries, but are failing to engage with pharmacy in the important clinical and patient-focused conversations,” the authors of the paper said in an email interview.
Mark Worman, McCann Health’s global marketing director, and Sandra Carey, president of the McCann Pharmacy Initiative, said pharma companies may be missing an opportunity in not recognizing pharmacists as highly educated expert healthcare professionals. While pharma has long-held communication channels and relationships with established patient-facing healthcare providers, the pharma industry’s connections to pharmacy are typically less involved.
“Much of pharma already calls on pharmacy and so their focus should be on changing the conversation and aligning the call to the customer needs and the professional requirements of pharmacy as the healthcare professional consumers likely see most often,” Worman and Carey said.
Some pharma companies are already making those kinds of changes. McCann Health pointed to GSK Consumer Healthcare’s pharmacy education program called myPharmAssist. The effort delivers custom content to the pharmacies as part of the drug company’s commitment “to enable shopper-patients to take better care of themselves, prevent chronic conditions, stay adherent to medicines, and reduce healthcare costs by using pharmacies as their health hub.”
Another way pharmacies and pharma could work together is through disease or health awareness campaigns.
“In the community setting, pharmacy has the face-to-face and personal connection with patients and health consumers should find increasing value in this relationship when it is personalized and outcomes focused,” the authors said. “… When pharma sees pharmacy in this new role, finding co-marketing opportunity should be easy for them.”
By Beth Snyder Bulik
Source: Fierce Pharma
AI is poised to significantly lower pharmaceutical R&D costs through efficient drug discovery, optimised clinical trials, and predictive data analysis, according to a GlobalData survey. The leading data and analytics company’s report, “The State of the Biopharmaceutical Industry – 2025,” highlights AI’s potential to boost productivity and cut costs in the coming year.
Gilead Sciences and LEO Pharma have announced a strategic partnership to advance LEO Pharma’s oral STAT6 program. This collaboration aims to develop treatments for patients suffering from inflammatory diseases such as atopic dermatitis, asthma, and COPD.
While deep-brain stimulation therapy has been available for people with Parkinson’s disease for decades, Medtronic has now received a European approval for what it describes as the first closed-loop therapy approach—allowing for self-adjusting neuromodulation in real time to help control the condition’s motor symptoms.
